These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 1534248)

  • 1. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group.
    Gundersen S; Kvinnsland S; Klepp O; Lund E; Hannisdal E; Høst H
    Eur J Cancer; 1992; 28(2-3):390-4. PubMed ID: 1534248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study. The Norwegian Breast Cancer Group.
    Gundersen S; Hannisdal E; Lundgren S; Wist E
    Eur J Cancer; 1994; 30A(12):1775-8. PubMed ID: 7880604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluorouracil, adriamycin and cyclophosphamide combined with high-dose medroxyprogesterone acetate in advanced breast cancer.
    Lopez M; Di Lauro L; Perno CF; Papaldo P; Barduagni M; Barduagni A
    Tumori; 1983 Dec; 69(6):545-51. PubMed ID: 6229920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients.
    Hupperets PS; Wils J; Volovics L; Schouten L; Fickers M; Bron H; Schouten HC; Jager J; Smeets J; de Jong J
    Ann Oncol; 1993 Apr; 4(4):295-301. PubMed ID: 8518219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
    Gundersen S; Kvinnsland S; Lundgren S; Klepp O; Lund E; Børmer O; Høst H
    Breast Cancer Res Treat; 1990 Nov; 17(1):45-50. PubMed ID: 2151369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer.
    Falkson CI; Falkson HC; Falkson G
    Am J Clin Oncol; 1988 Aug; 11(4):431-4. PubMed ID: 2970218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative evaluation of the effectiveness of induction chemotherapy using the Cooper, FAC and FAC + MPA protocols in patients with locally advanced breast cancer].
    Pawlicki M; Brandys A; Zuchowska B
    Nowotwory; 1986; 36(2):124-9. PubMed ID: 2947046
    [No Abstract]   [Full Text] [Related]  

  • 8. Advanced breast cancer: response to high dose oral medroxyprogesterone acetate.
    Hedley D; Dalgleish A; Raghavan D; Tattersall MH; Coates A; Fox R
    Aust N Z J Med; 1984 Jun; 14(3):251-4. PubMed ID: 6238589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer.
    Hortobagyi GN; Buzdar AU; Frye D; Yap HY; Hug V; Pinnamaneni K; Fraschini G; Halvorson HC; Blumenschein GR
    Breast Cancer Res Treat; 1985; 5(3):321-6. PubMed ID: 3161565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer.
    Tominaga T; Abe O; Ohshima A; Hayasaka H; Uchino J; Abe R; Enomoto K; Izuo M; Watanabe H; Takatani O
    Eur J Cancer; 1994; 30A(7):959-64. PubMed ID: 7946592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
    Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
    Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer].
    Aikawa T; Yayoi E; Takatsuka Y; Maeura Y; Miyauchi K
    Gan To Kagaku Ryoho; 1991 May; 18(6):995-1002. PubMed ID: 1827575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
    Mauriac L; Durand M; Bonichon F; Chauvergne J
    Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of hematological and general tolerance to CMF by high-dose medroxyprogesterone acetate (HD-MPA) adjuvant treatment for primary node positive breast cancer (analysis of 100 patients).
    Focan C; Baudoux A; Beauduin M; Bunescu U; Dehasque N; Dewasch L; Lobelle JP; Longeval E; Majois F; Salamon E
    Anticancer Res; 1986; 6(5):1095-9. PubMed ID: 2948442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.
    Viladiu P; Alonso MC; Avella A; Beltrán M; Borrás J; Ojeda B; Bosch FX
    Cancer; 1985 Dec; 56(12):2745-50. PubMed ID: 3902200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)].
    Mitsuyama S; Ohno S; Koga T; Takayama T; Yamashita J; Ogawa M; Shirouzu K; Sugimachi K; Nomura Y; Ogawa N
    Gan To Kagaku Ryoho; 1999 Nov; 26(13):2029-36. PubMed ID: 10584567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
    Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M
    Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients.
    Martoni A; Longhi A; Canova N; Pannuti F
    Oncology; 1991; 48(1):1-6. PubMed ID: 1824798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive short-term chemotherapy in patients with advanced breast cancer.
    Wander HE; Nagel GA; Luig H; Emrich D
    Klin Wochenschr; 1987 Apr; 65(7):317-23. PubMed ID: 2953934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.